Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- TRANSLATIONAL LUNG CANCER RESEARCH15(1) · 2026
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 3.5
- ISSN
- 2218-6751
저자
- Kim, Min Jee제1저자Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
- Jung, JungheeUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
- Ji, WonjunUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
- Choi, Chang-MinUniv Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea
- Kim, Seung JoonCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
- Cho, Hyung JunCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
- Hwang, Yong GiCatholic Univ Korea, Seoul St Marys Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
- Kim, Eun YoungYonsei Univ, Dept Internal Med, Div Pulm & Crit Care Med, Coll Med, Seoul, South Korea
- Lee, Shin YupKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
- Yoo, Seung SooYangsan Hosp, Yangsan, South Korea
- Choi, SunhaKyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea
- Oh, In-JaeChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
- Kim, Young-ChulChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
- Park, Chul-KyuChonnam Natl Univ, Dept Internal Med, Div Pulm & Crit Care Med, Med Sch, Jeonnam, South Korea
- 윤성훈Pusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea
- 김윤성Pusan Natl Univ, Dept Internal Med, Sch Med, Yangsan, South Korea
- 김미현Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
- 이민기Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
- 엄중섭Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
- 김수한Pusan Natl Univ, Pusan Natl Univ Hosp, Dept Internal Med, Sch Med, Busan, South Korea
- Lee, Jeong EunChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med, Daejeon, South Korea
- Chung, ChaeukChungnam Natl Univ, Coll Med, Dept Internal Med, Div Pulmonol & Crit Care Med, Daejeon, South Korea
- Yeo, Chang DongCatholic Univ Korea, Eunpyeong St Marys Hosp, Dept Internal Med, Coll Med,Div Pulmonary & Crit Care M, Seoul, South Korea
- Lee, Sang HaakCatholic Univ Korea, Eunpyeong St Marys Hosp, Dept Internal Med, Coll Med,Div Pulmonary & Crit Care M, Seoul, South Korea
- Lee, Jae Cheol교신저자Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, 88 Olympicro 43-gil, Seoul 05505, South Korea
초록
Background: Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors improve outcomes in EGFR T790M-positive non-small cell lung cancer (NSCLC), but the prognostic value of plasma-detected T790M remains uncertain. We evaluated the clinical significance of baseline plasma T790M in patients treated with lazertinib, accounting for metastatic distribution and coexisting genomic alterations. Methods: In this prospective multicenter cohort, we analyzed 117 patients with EGFR-mutant NSCLC who received lazertinib after T790M confirmation in tissue or plasma. Plasma EGFR mutations were profiled using next-generation sequencing before treatment. Progression-free survival (PFS) and overall survival (OS) were compared by plasma T790M status, metastatic sites, and co-alterations. Results: Of 117 patients, 92 were plasma T790M-positive and 25 were plasma T790M-negative. Plasma T790M positivity was associated with shorter PFS (10.0 vs. 23.0 months, P=0.03) and OS (20.0 months vs. not reached, P=0.006). All patients with liver or adrenal metastases were plasma T790M-positive, and involvement of either site predicted poorer outcomes than in patients without these metastases. Bone metastasis also portended a worse prognosis, irrespective of plasma T790M status. Among co-alterations, EGFR C797S or MYC alterations correlated with shorter PFS. Conclusions: Baseline plasma T790M, interpreted alongside metastatic distribution, provided prognostic information in EGFR-mutant NSCLC treated with lazertinib. Liver and adrenal metastases occurred exclusively in plasma T790M-positive patients and were associated with markedly worse outcomes, consistent with a ctDNA-shedding phenotype. Bone metastasis was an adverse prognostic factor independent of plasma T790M, underscoring the combined prognostic impact of molecular and metastatic features.
키워드
lazertinibmetastatic distributionNon-small cell lung cancer (NSCLC)plasma epidermal growth factor receptor T790M (plasma EGFR T790M)prognosis
식별자
- Scopus EID
- 2-s2.0-105028526977
- WoS UID
- 001688005100001



로그인
연구물 목록으로